Dan Hesse

Dan Hesse

Auto-generated profile, based on publicly available information

Dan Hesse

Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital, Rigshospitalet, Denmark

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2013 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
HSHelle Bach Søndergaard
Helle Bach Søndergaard
DHDan Hesse
Dan Hesse
MKMartin Krakauer
Martin Krakauer
PSPer Soelberg Sørensen
Per Soelberg Sørensen
FSFinn Sellebjerg
Finn Sellebjerg
Background: microRNAs (miRNAs) regulate the expression of the genome at the post-transcriptional level. They play a role in autoimmunity and inflammation, and show potential for use as therapeutic targets in many diseases. With the recent detection of miRNAs in body fluids, the possibility for using miRNAs as diagnostic biomarkers has emerged. Objective: We assessed whether miRNAs contribute to the altered immune activation state in relapsing–remitting multiple sclerosis (RRMS) patients and investigated the possible use of miRNAs as diagnostic biomarkers in multiple sclerosis (MS). Methods: We performed global miRNA expression profiling analysis in peripheral blood mononuclear cells (PBMCs) and selected miRNAs were measured in plasma. We detected expression of miRNAs by real-time qPCR and compared results with cytokines related to inflammation and disease activity. Selected miRNAs were analyzed in PBMC subpopulations, after isolating them by magnetic bead separation. Results: We found that among validated miRNAs, let-7d correlated with the pro-inflammatory cytokine interleukin-1B. The miR-145 was 3-fold up-regulated in MS patients; its possible use as a diagnostic biomarker in PBMCs, plasma and serum was confirmed by ROC-curve analysis (Area under the curve (AUC) 0.785, p = 0.0004; 0.785, p = 0.004; 0.981, P < 0.0001, respectively). Conclusions: RRMS patients in remission had altered expression of miRNAs. We validated miR-145 as a potential diagnostic biomarker for the diagnosis of MS in blood, plasma and serum.

4 August 2009 in Neurology
Verified
Journal Article
Closed access
PDF file
DHD. Hesse
D. Hesse
FSF. Sellebjerg
F. Sellebjerg
PSP. Soelberg Sorensen
P. Soelberg Sorensen
Background: In patients with multiple sclerosis (MS), neutralizing antibodies (NAbs) appearing during treatment with interferon (IFN) β reduce or in high concentrations abolish bioactivity and therapeutic efficacy. In vivo MxA induction by IFNβ is used as a marker of biologic response to IFNβ. It has been argued that despite absence of MxA induction measured by PCR, some bioactivity might be preserved. In a cohort study, we measured gene expression by gene chip analysis in NAb-negative and NAb-positive patients to test that hypothesis. Methods: The effect of IFNβ was studied by comparing samples collected before and 9–12 hours after an injection. The cohort consisted of 12 NAb-positive patients without MxA response and 12 NAb-negative patients with preserved response. MxA in vivo response was determined in whole blood using real-time PCR. Screening for IFNβ-regulated genes in mononuclear cells was done using gene chips. False discovery rate (FDR) analysis was used as statistical tool. Results: Of 8,793 genes, 5,593 were detectable in at least one patient in both groups. Of these, calculation of FDR revealed 1,077 IFNβ-regulated genes at a 5% level in NAb-negative patients. The corresponding number of IFNβ-regulated genes in NAb-positive patients was zero. Conclusion: In neutralizing antibody (NAb)–positive patients without an MxA response, we were not able to detect differential expression of any of the 1077 interferon (IFN) β-regulated genes identified in NAb-negative patients. Lack of MxA in vivo response in patients with multiple sclerosis with NAbs is a reliable marker of a completely blocked biologic response to IFNβ, with no indication of residual bioactivity.

14 September 2012 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
JCJeppe Romme Christensen
Jeppe Romme Christensen
LBLars Börnsen
Lars Börnsen
DHDan Hesse
Dan Hesse
MKMartin Krakauer
Martin Krakauer
PSPer Soelberg Sørensen
Per Soelberg Sørensen
FSFinn Sellebjerg
Finn Sellebjerg
Numerous cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS), but studies are often limited to whole blood (WB) or peripheral blood mononuclear cells (PBMCs), thereby omitting important information about the cellular origin of the cytokines. Knowledge about the relation between blood and cerebrospinal fluid (CSF) cell expression of cytokines and the cellular source of CSF cytokines is even more scarce.

25 July 2007 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
DHD. Hesse
D. Hesse
PSP. S. Sørensen
P. S. Sørensen

17 November 2009 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
FSF. Sellebjerg
F. Sellebjerg
MKMartin Krakauer
Martin Krakauer
DHD. Hesse
D. Hesse
LRL. P. Ryder
L. P. Ryder
IAI. Alsing
I. Alsing
PSP. Soelberg Sørensen
P. Soelberg Sørensen
Objective:  Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)‐β. NAbs impair the effect of treatment. The biological effect of IFN‐β can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN‐β. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN‐β, and measured their expression in MS patients with different NAb levels.Methods:  Gene expression was studied on DNA arrays in untreated patients, in NAb negative patients, and in MS patients with varying NAb levels 9–12 h and 36–48 h after IFN‐β administration. The expression of selected genes was measured by real‐time PCR. NAb levels were assessed by a cytopathic effect assay.Results:  Several hundred genes were induced 9–12 h after an injection of IFN‐β. The molecules CXCL10, CCL2 and IFI27 were among the most strongly induced. Gene induction was generally much less pronounced after 36–48 h, but IFI27 remained strongly induced. The strong induction of these molecules and MxA was confirmed by real‐time PCR. Induction of MxA, CCL2, CXCL10 and IFI27 was reduced in patients with low NAb levels and lost in patients with intermediate/high NAb levels.Conclusion:  We identify IFI27, CCL2 and CXCL10 as sensitive biomarkers for the response to IFN‐β. The expression of these markers adequately reflects bioactivity of IFN‐ß as documented by the decreased induction in low NAb‐positive patients and the lost induction in patients with moderate/high NAb levels.

17 January 2011 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
DHD. Hesse
D. Hesse
MKMartin Krakauer
Martin Krakauer
HLH. Lund
H. Lund
HSH. B. Søndergaard
H. B. Søndergaard
SLS. J. W. Limborg
S. J. W. Limborg
FSF. Sellebjerg
F. Sellebjerg